Tiotidine, a new H2-receptor antagonist, is a potent inhibitor of nocturnal acid secretion in duodenal ulcer patients.
The efficacy of tiotidine, a new H2-receptor antagonist, in reducing nocturnal acid secretion of duodenal ulcer patients (N = 12, ages 21-60 years) was investigated. Different doses of tiotidine, 25, 50, 100, and 150 mg or placebo, were given as a single oral dose and acid secretion collected overnight. Tiotidine produced a significant, prolonged, and dose-related reduction of the nocturnal acid secretion without important side effects. The inhibition of cumulative H+ secretion after 25, 50, 100, and 150 mg tiotidine was 80, 89, 96, and 98% of that observed after placebo, while 300 mg of cimetidine caused an 87% inhibition. Compared to cimetidine, tiotidine appears to be approximately eight times more potent on a molar basis than cimetidine as an inhibitor of acid secretion, and the tiotidine effect is more prolonged. This strong and safe H2-receptor antagonist may be an important addition to the treatment of acid hypersecretory states.
D000328:Adult; D002927:Cimetidine / Q000627:therapeutic use / Q000031:analogs & derivatives; D004341:Drug Evaluation; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005744:Gastric Acid / Q000378:metabolism*; D006146:Guanidines / Q000008:administration & dosage / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D006146:Guanidines; D006635:Histamine H2 Antagonists; D013844:Thiazoles; D002927:Cimetidine; C023990:tiotidine